147 related articles for article (PubMed ID: 37336590)
21. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
[TBL] [Abstract][Full Text] [Related]
22. Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints.
Chen YC; Kuo SF; Chen FJ; Lee CH
Mycoses; 2017 Feb; 60(2):89-95. PubMed ID: 27621210
[TBL] [Abstract][Full Text] [Related]
23. Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals.
Colombo AL; Garnica M; Aranha Camargo LF; Da Cunha CA; Bandeira AC; Borghi D; Campos T; Senna AL; Valias Didier ME; Dias VC; Nucci M
Med Mycol; 2013 Jan; 51(1):38-44. PubMed ID: 22762208
[TBL] [Abstract][Full Text] [Related]
24. Clinical manifestations of candidemia caused by uncommon Candida species and antifungal susceptibility of the isolates in a regional hospital in Taiwan, 2007-2014.
Liu WL; Lai CC; Li MC; Wu CJ; Ko WC; Hung YL; Tang HJ; Hsueh PR
J Microbiol Immunol Infect; 2019 Aug; 52(4):612-619. PubMed ID: 28886952
[TBL] [Abstract][Full Text] [Related]
25. Prior colonisation with Candida species fails to guide empirical therapy for candidaemia in critically ill adults.
Troughton JA; Browne G; McAuley DF; Walker MJ; Patterson CC; McMullan R
J Infect; 2010 Nov; 61(5):403-9. PubMed ID: 20849877
[TBL] [Abstract][Full Text] [Related]
26. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
[TBL] [Abstract][Full Text] [Related]
27. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.
Lortholary O; Desnos-Ollivier M; Sitbon K; Fontanet A; Bretagne S; Dromer F;
Antimicrob Agents Chemother; 2011 Feb; 55(2):532-8. PubMed ID: 21078946
[TBL] [Abstract][Full Text] [Related]
28. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
29.
Bordallo-Cardona MÁ; Agnelli C; Gómez-Nuñez A; Sánchez-Carrillo C; Bouza E; Muñoz P; Escribano P; Guinea J
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397068
[TBL] [Abstract][Full Text] [Related]
30. Candida bloodstream infection among children hospitalised in three public-sector hospitals in the Metro West region of Cape Town, South Africa.
Gebremicael MN; Nuttall JJC; Tootla HD; Khumalo A; Tooke L; Salie S; Muloiwa R; Rhoda N; Basera W; Eley BS
BMC Infect Dis; 2023 Feb; 23(1):67. PubMed ID: 36737689
[TBL] [Abstract][Full Text] [Related]
31. Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.
Puig-Asensio M; Fernández-Ruiz M; Aguado JM; Merino P; Lora-Pablos D; Guinea J; Martín-Dávila P; Cuenca-Estrella M; Almirante B
Antimicrob Agents Chemother; 2016 Jun; 60(6):3291-300. PubMed ID: 26976872
[TBL] [Abstract][Full Text] [Related]
32. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
[TBL] [Abstract][Full Text] [Related]
33. Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study.
Jensen RH; Johansen HK; Søes LM; Lemming LE; Rosenvinge FS; Nielsen L; Olesen B; Kristensen L; Dzajic E; Astvad KM; Arendrup MC
Antimicrob Agents Chemother; 2015 Dec; 60(3):1500-8. PubMed ID: 26711776
[TBL] [Abstract][Full Text] [Related]
34. Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel.
Ben-Ami R; Rahav G; Elinav H; Kassis I; Shalit I; Gottesman T; Megged O; Weinberger M; Ciobotaro P; Shitrit P; Weber G; Paz A; Miron D; Oren I; Bishara J; Block C; Keller N; Kontoyiannis DP; Giladi M;
Clin Microbiol Infect; 2013 Aug; 19(8):752-6. PubMed ID: 23005038
[TBL] [Abstract][Full Text] [Related]
35. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata.
Singh-Babak SD; Babak T; Diezmann S; Hill JA; Xie JL; Chen YL; Poutanen SM; Rennie RP; Heitman J; Cowen LE
PLoS Pathog; 2012; 8(5):e1002718. PubMed ID: 22615574
[TBL] [Abstract][Full Text] [Related]
36.
Maphanga TG; Mpembe RS; Naicker SD; Govender NP;
Microbiol Spectr; 2022 Feb; 10(1):e0171721. PubMed ID: 35196811
[TBL] [Abstract][Full Text] [Related]
37. Candida auris candidaemia in Indian ICUs: analysis of risk factors.
Rudramurthy SM; Chakrabarti A; Paul RA; Sood P; Kaur H; Capoor MR; Kindo AJ; Marak RSK; Arora A; Sardana R; Das S; Chhina D; Patel A; Xess I; Tarai B; Singh P; Ghosh A
J Antimicrob Chemother; 2017 Jun; 72(6):1794-1801. PubMed ID: 28333181
[TBL] [Abstract][Full Text] [Related]
38. Antifungal susceptibility trend and analysis of resistance mechanism for Candida species isolated from bloodstream at a Japanese university hospital.
Sakagami T; Kawano T; Yamashita K; Yamada E; Fujino N; Kaeriyama M; Fukuda Y; Nomura N; Mitsuyama J; Suematsu H; Watanabe H; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
J Infect Chemother; 2019 Jan; 25(1):34-40. PubMed ID: 30401513
[TBL] [Abstract][Full Text] [Related]
39. Microevolution of Candida glabrata (Nakaseomyces glabrata) during an infection.
López-Marmolejo AL; Hernández-Chávez MJ; Gutiérrez-Escobedo G; Selene Herrera-Basurto M; Mora-Montes HM; De Las Peñas A; Castaño I
Fungal Genet Biol; 2024 Jun; 172():103891. PubMed ID: 38621582
[TBL] [Abstract][Full Text] [Related]
40. Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?
Le A; Farmakiotis D; Tarrand JJ; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
